Abstract Details

Title The Relationship Between Disordered Sleep and Pain Perception in Patients with Peripheral Neuropathy

Topic Sleep

Presentation(s) P10 - Poster Session 10 (11:45 AM-12:45 PM)

Poster/Presentation
Number 9-010

Objective To assess the relationship between disordered sleep and pain perception in patients with peripheral neuropathy.

Background The crucial role of sleep in the modulation of pain is well established, and there is evidence to suggest that the treatment of disordered sleep in patients with neuropathic pain improves pain perception. However, studies on this topic remain limited in painful peripheral neuropathy.

Design/Methods The associations between disordered sleep, pain perception, and neuropathic symptoms were examined cross-sectionally in 24 subjects with peripheral neuropathy diagnosed by a neurologist. For each subject validated scales assessing sleep quality (Neuro-QoL Sleep, Insomnia Severity Index (ISI), Epworth Sleepiness Scale (ESS), and Pittsburgh Sleep Quality Index (PSQI)), pain perception (Brief Pain Inventory (BPI), Pain Catastrophizing Scale (PCS)), and neuropathic symptoms (Michigan Neuropathy Screening Instrument (MNSI) were compared. All models were adjusted for age, sex, body mass index, history of sleep disorder, and mood disorder (depression/anxiety).

Results 75% of participants enrolled were female (18/24) with a mean age of 66.9 years (SD ± 10.5). Worse pain severity measured by BPI was associated with higher ISI (p=0.020), PSQI (p=0.047), and Neuro QoL Sleep (p=0.01), but not ESS (p=0.241) or FOSQ-10 (p=0.824). Similarly, higher PCS was associated with higher ISI (p=0.003), PSQI (p=0.09) and Neuro-QoL Sleep (p=0.001), but not ESS (p=0.155) or FOSQ-10 (p=0.410). MNSI score ≥7 was associated with worse sleep outcomes on all scales - ISI (p=0.009), PSQI (p=.048), Neuro-QoL Sleep (p=0.01), FOSQ-10 (p=0.005), ESS (p=0.01), FOSQ-10 (p=0.005).

Conclusions We demonstrate associations between several measures of disordered sleep and elevated pain perception and neuropathic symptoms in patients with peripheral neuropathy. Importantly, disordered sleep is modifiable with targeted pharmacologic and nonpharmacologic interventions - establishing and characterizing this relationship therefore has important implications for the use of current therapies and the development of new therapies targeting sleep and neuropathic pain.

Authors/Disclosures
Julia Greenberg, MD PRESENTER	Dr. Greenberg has a non-compensated relationship as a Editorial Board Member with Neurology Resident and Fellow Section that is relevant to AAN interests or activities.
Sophia T. Tong	Ms. Tong has nothing to disclose.
Christina Marini	Ms. Marini has nothing to disclose.
Azizi Seixas	No disclosure on file
Kiril Kiprovski, MD (NYU-Langone Health)	Dr. Kiprovski has nothing to disclose.
Lisa Doan	No disclosure on file
Ricardo Osorio (NYU Langone Health)	No disclosure on file
Sujata P. Thawani, MD (NYU Neurology Associates)	Dr. Thawani has nothing to disclose.

��ɫ��

��ɫ��